title: Diagnostic Performance of Whole-Body Diffusion-Weighted Imaging Compared to PET-CT Plus Brain MRI in Staging Clinically Resectable Lung Cancer.
abstract: BACKGROUND
  Precise staging of lung cancer is usually evaluated by PET-CT and brain MRI. Recently, however, whole-body diffusion-weighted magnetic resonance imaging (WB-DWI) has be applied. The aim of this study is to determine whether the diagnostic performance of lung cancer staging by WB-DWI is superior to that of PET-CT+brain MRI.
  
  
  METHODS
  PET-CT + brain MRI and WB-DWI were used for lung cancer staging before surgery with 59 adenocarcinomas, 16 squamous cell carcinomas and 6 other carcinomas.
  
  
  RESULTS
  PET-CT + brain MRI correctly identified the pathologic N staging in 67 patients (82.7%), with overstaging in 5 (6.2%) and understaging in 9 (11.1%), giving a staging accuracy of 0.827. WB-DWI correctly identified the pathologic N staging in 72 patients (88.9%), with overstaging in 1 (1.2%) and understaging in 8 patients (9.9%), giving a staging accuracy of 0.889. There were no significant differences in accuracies. PET-CT + brain MRI correctly identified the pathologic stages in 56 patients (69.1%), with overstaging in 7 (8.6%) and understaging in 18 (22.2%), giving a staging accuracy of 0.691. WB-DWI correctly identified the pathologic stages in 61 patients (75.3%), with overstaging in 4 (4.9%) and understagings in16(19.7%), giving a staging accuracy of 0.753. There were no significant difference in accuracies.
  
  
  CONCLUSIONS
  Diagnostic efficacy of WB-DWI for lung cancer staging is equivalent to that of PET-CT + brain MRI.
authors.affiliation: Department of Thoracic Surgery, Kanazawa Medical University, Ishikawa, Japan E-mail : usuda@kanazawa-med.ac.jp.
authors.forename: Katsuo
authors.initials: K
authors.lastname: Usuda
authors.forename: Motoyasu
authors.initials: M
authors.lastname: Sagawa
authors.forename: Sumiko
authors.initials: S
authors.lastname: Maeda
authors.forename: Nozomu
authors.initials: N
authors.lastname: Motono
authors.forename: Makoto
authors.initials: M
authors.lastname: Tanaka
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Machida
authors.forename: Takuma Matsui Munetaka
authors.initials: TM
authors.lastname: Matoba
authors.forename: Naoto
authors.initials: N
authors.lastname: Watanabe
authors.forename: Hisao
authors.initials: H
authors.lastname: Tonami
authors.forename: Yoshimichi
authors.initials: Y
authors.lastname: Ueda
authors.forename: Hidetaka
authors.initials: H
authors.lastname: Uramoto
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018288:Carcinoma, Small Cell / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000601:surgery; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000601:surgery; D038524:Diffusion Magnetic Resonance Imaging / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000601:surgery; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging / Q000379:methods*; D009367:Neoplasm Staging / Q000592:standards*; D000072078:Positron Emission Tomography Computed Tomography / Q000379:methods*; D011379:Prognosis; D051598:Whole Body Imaging / Q000379:methods*